EXAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exact Sciences Corp (EXAS) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has positive revenue growth and is being acquired by Abbott Laboratories, the financial performance shows significant net income and EPS declines. Additionally, hedge funds are selling, and there are no strong technical or proprietary trading signals to support an immediate buy decision.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 49.464, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the price is hovering near key pivot levels, with no strong breakout or breakdown signals.
Abbott's strong financial position and strategic focus on cancer diagnostics could benefit Exact Sciences in the long term.
Hedge funds are selling heavily, with a 614.09% increase in selling activity over the last quarter. Insider trading trends are neutral, and the stock has been downgraded by Evercore ISI to 'In Line' from 'Outperform.' Additionally, the company's net income and EPS have dropped significantly, raising concerns about profitability.
In 2025/Q4, revenue increased by 23.12% YoY to $878.38 million, showing strong growth. However, net income dropped by 90.06% YoY to -$85.96 million, and EPS fell by 90.36% YoY to -$0.45, indicating significant profitability challenges. Gross margin improved to 70.11%, up 16.52% YoY.
Evercore ISI downgraded Exact Sciences to 'In Line' from 'Outperform' with an unchanged price target of $105, reflecting a cautious outlook on the stock.
